Thus, our studies suggest that in addition to directly targeting oncogenic KRAS and its downstream effectors and glycolytic pathways [29–32], targeting the upstream inducers of KRAS hyperactivation may constrain the heightened aerobic glycolysis for cancer prevention and therapy (Fig. 3). This evidence concerns the gene KRAS and cancer.